Welcome to our dedicated page for NOVO NORDISK A S SEC filings (Ticker: NONOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk A/S filings document Form 6-K reports from a Danish foreign issuer, including interim financial results, commercial updates, pipeline disclosures, and capital-management actions. The reports describe sales and operating profit by areas such as Obesity care, US Operations, International Operations, and GLP-1 products, as well as pricing effects tied to the 340B Drug Pricing Program.
The filing record also covers B-share repurchase programs, treasury-share balances, share capital, and safe-harbor transaction reporting under European market-abuse rules. Product and research disclosures include Wegovy, Awiqli, semaglutide-based obesity therapies, and zenagamtide program activity in diabetes and obesity.
Novo Nordisk will acquire Akero Therapeutics for $54 per share in cash, representing total consideration of about $4.7B, plus a contingent value right of $6 per share (about $0.5B) on closing. The deal adds Akero's FGF21 analogue efruxifermin (EFX), described as the only therapy to show significant fibrosis regression in phase 2 patients with compensated cirrhosis (F4).
EFX is positioned to treat metabolic dysfunction-associated steatohepatitis (MASH), a comorbidity closely linked to diabetes and obesity; the filing notes >40% of MASH patients have type 2 diabetes and >80% are overweight or living with obesity. Novo Nordisk highlights ongoing programs including SYNCHRONY Histology, SYNCHRONY Outcomes, and SYNCHRONY Real-World to evaluate EFX across F1–F4 disease stages, with once-weekly subcutaneous dosing reported as generally well tolerated in trials to date.